← feed

Is NCT02568306 results overdue?

Yes — results are overdue. Primary completion was 2017-02-07; the FDAAA-801 reporting deadline (2018-02-07) passed 3056 days ago and no results are posted on ClinicalTrials.gov.

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

NCT IDNCT02568306 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-02-07 (ACTUAL)
Reporting deadline2018-02-07 (completion + 365d)
Days overdue3056
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 b678f6740dfb7000… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02568306. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →